Effect of 25 and 100 mg spironolactone on quality of life, ejection fraction and readmission in systolic heart failure patients with reduced ejection fraction

Effect of 25 and 100 mg spironolactone on quality of life, ejection fraction and readmission in systolic heart failure patients with reduced ejection fraction in Imam Khomeini hospital in Ahvaz

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220404054403N1

Enrollment

Registered

2022-05-30

Start date

2022-07-02

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systolic heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: 25 mg spironolactone group daily for 6 months. Intervention 2: Intervention group: 100 mg spironolactone group daily for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute systolic heart failure (EF <40) A history of hospitalization in the last 6 months

Exclusion criteria

Exclusion criteria: Known contraindications for spironolactone or prior documented intolerance to an aldosterone receptor antagonist Significant laboratory abnormalities (potassium = 5.1 mmol) Mental disorders suspected to interact with study outcome Pregnant or nursing women Significant renal dysfunction Significant hypotension (lower than 90 mm Hg systolic or 60 mm Hg diastolic) CRT or ICD

Design outcomes

Primary

Measure	Time frame
Ejection fraction. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: Echocardiography.;Quality of life. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: Minnesota Questionnaire.;Readmission. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: 6 MIN Walk test.	—

Measure

Time frame

Ejection fraction. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: Echocardiography.;Quality of life. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: Minnesota Questionnaire.;Readmission. Timepoint: Before the intervention and 6 months after drug administration. Method of measurement: 6 MIN Walk test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Lalvand

Ahvaz University of Medical Sciences

hosseinlalvand69@gmail.com+98 61 3222 8037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026